Lyra Therapeutics, a Phase 2 biotech targeting ear, nose, and throat diseases, filed on Friday with the SEC to raise up to $58 million in an initial public offering.
The Watertown, MA-based company was founded in 2005 and plans to list on the Nasdaq under the symbol LYRA. BofA Securities, Jefferies and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Phase 2 ENT biotech Lyra Therapeutics files for a $58 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
